WHO WE ARE

Eos Biosciences, Inc. is a Nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology to facilitate the effective delivery of approved and novel therapeutics to disease sites.

The company’s most advanced programs are oncology-focused. Eos also has several programs under development, including targeting therapeutics across the blood brain barrier and packaging and delivery of nucleic acid therapeutics.

LATEST NEWS

2003, 2019

Eos Biosciences Issued Patent for New Approach to Shuttle Therapeutics Across the Blood‐Brain Barrier to Treat Brain Diseases

LOS ANGELES--(BUSINESS WIRE)--Eos Biosciences, Inc. (Eos), a nanomedicines company developing an efficient and versatile nanobiologic particle-based platform technology (Eosomes), announced that the U.S. Patent and Trademark Office has granted Eos Biosciences Patent No. 10,183,078, relating to a novel approach of using HER3-targeted Eosomes as a shuttle system for transporting various [...]

1505, 2018

Eos Biosciences will attend the 2018 Biotechnology Innovation Organization (BIO) International Convention in Boston, June 2-5, 2018

Eos Biosciences will attend the 2018 Biotechnology Innovation Organization (BIO) International Convention being held June 2-5, 2018, in Boston. Eos Biosciences’ Chief Executive Officer, Omar Haffar, Ph.D. and Chief Financial Officer, Thomas Plotts will attend the BIO International Convention.

1710, 2017

Eos Biosciences Announces Issuance of Additional U.S. Patent For Targeted Breast Cancer Therapy

Los Angeles, CA- October 17, 2017- Eos Biosciences, Inc., a bio-targeted nanomedicines company developing a novel nanobiologic particle drug delivery platform technology (Eosomes), and a proprietary oncology-specific product pipeline, announced that the U.S. Patent and Trademark Office has now issued Eos Biosciences a second patent, U.S. Patent No. 9,789,201, for [...]